Want to see CYTK full AI Analyst Report?
CYTK Stock Chart & Stats
$80.74
$0.81(1.01%)
At close: 4:00 PM EDT
$80.74
$0.81(1.01%)
Day’s Range― - ―
52-Week Range$34.60 - $88.31
Previous CloseN/A
Volume899.92K
Average Volume (3M)2.19M
Market Cap
$10.63B
Enterprise Value$11.35K
Total Cash (Recent Filing)$1.17B
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Oct 29, 2026EPS Estimate
-1.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.21
Shares Outstanding139,023,420
10 Day Avg. Volume1,513,183
30 Day Avg. Volume2,192,944
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)-11.56
Price to Sales (P/S)86.62
P/FCF Ratio-14.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$111.33Price Target Upside37.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-6.09
Revenue Forecast (FY)$143.11M
Bulls Say, Bears Say
Bulls Say
Commercial Launch TractionSustained quarter‑over‑quarter growth in dispenses and $25.3M in Q2 product revenue demonstrate early commercial product–market fit. Durable adoption by prescribers, growing prescriptions and REMS certifications support a scalable U.S. launch that can transition the company toward recurring product revenues over the next 6–18 months.
Strengthened Cash RunwayA post‑offering cash balance near $1.7B materially extends runway to fund commercialization, regulatory filings and ongoing late‑stage trials. This reduces near‑term refinancing pressure, allowing management to execute launch plans and pivotal programs without immediate dependence on dilutive raises, improving execution optionality.
Positive Pivotal Data & Regulatory PathStatistically positive pivotal results and a planned sNDA materially de‑risk aficamten’s development trajectory, increasing the likelihood of label expansion and new indications. Combined with an existing MAPLE‑HCM PDUFA date, this strengthens the company’s product franchise and long‑term revenue potential independent of one‑time partner milestones.
Bears Say
Heavy Cash BurnVery large negative operating and free cash flows reflect persistent high spending on launches and R&D. Even with current cash, sustained negative cash generation means the company will either need to realize meaningful product revenue growth or access capital markets again, creating structural financing and execution risk over the medium term.
Weak Capital StructureNegative equity combined with substantial absolute debt levels indicates an impaired balance sheet that limits flexibility. This structural weakness raises refinancing and covenant risk, can increase cost of capital, and constrains strategic choices if product ramps or milestone receipts fall short of expectations.
Revenue Volatility & Milestone DependenceLarge year‑over‑year swings driven by licensing/milestone timing rather than recurring sales highlight unreliable top‑line predictability. Until MYQORZO and other assets produce sustained, predictable product revenue, planning and funding for continued commercialization and R&D will be more exposed to timing of partner events and one‑off payments.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $34.60 and its highest was $88.31 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $10.63B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Oct 29, 2026 which is in 76 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 06, 2026. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$1.628 by $0.128.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.46.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 139,023,420 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.5 in its last earnings report, beating expectations of -$1.628. Following the earnings report the stock price went down -5.665%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$111.33 (37.89% Upside)
$111.33 (37.89% Upside)
Blogger Sentiment
Neutral
CYTK Sentiment 57%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 766.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
57.02%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial operational and clinical progress: strong early commercial momentum for MYQORZO (rapidly growing prescriptions, rising awareness, >700 prescribers and >1,500 dispensed patients), pivotal ACACIA-HCM positive results with planned sNDA submission, successful European regulatory steps and a $760M financing that boosted cash to ~$1.7B. These strategic and scientific achievements were balanced against near-term financial headwinds including a YOY revenue decline driven by absence of milestone revenue, a wider GAAP net loss ($198.8M), sharply higher SG&A tied to launch costs and upwardly revised 2026 expense guidance. Overall, the operational wins, pivotal data and strong cash position indicate a constructive outlook for growth and future approvals, though investors should expect continued elevated spending as the company scales commercialization and pursues regulatory filings.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$111.33
▲(37.89% Upside)
Technical Analysis
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
―
Ownership Overview
0.71% Insiders
34.89% Mutual Funds
8.36% Other Institutional Investors
32.27% Public Companies and
Individual Investors